I-Gefitinib ePhakathi CAS 199327-61-2 Ubunyulu > 99.0% (HPLC)
I-Shanghai Ruifu Chemical Co., Ltd. ngumenzi ohamba phambili we-7-Methoxy-6- (3-Morpholin-4-ylpropoxy)quinazolin-4 (3H)-One (CAS: 199327-61-2) kunye nomgangatho ophezulu, ophakathi. yeGefitinib (CAS: 184475-35-2).I-Ruifu Chemical inokubonelela ngenkonzo yehlabathi jikelele, ixabiso elikhuphisanayo, inkonzo egqwesileyo, encinci kunye nezixa ezininzi ezikhoyo.Thenga abaPhakathi beGefitinib,Please contact: alvin@ruifuchem.com
| Igama leMchiza | 7-Methoxy-6-(3-Morpholin-4-ylpropoxy)quinazolin-4(3H)-Inye |
| Izithethantonye | 7-Methoxy-6-(3-Morpholinopropoxy)quinazolin-4(3H)-Enye;7-Methoxy-6-[3- (4-Morpholinyl) propoxy] -4 (3H) -Quinazolinone;7-Methoxy-6-(3-Morpholinopropoxy)quinazolin-4-One |
| ukungcola | ukungcola kweGefitinib 5;Gefitinib EP Ukungcola A |
| Ubume beStokhwe | Kwi-Stock, iMveliso yoRhwebo |
| Inombolo yeCAS | 199327-61-2 |
| Ifomula yeemolekyuli | I-C16H21N3O4 |
| Ubunzima beMolekyuli | 319.36 g/mol |
| Indawo yokunyibilika | 242.0~247.0℃ |
| Ukuxinana | 1.32±0.10 g/cm3 |
| I-COA kunye ne-MSDS | Iyafumaneka |
| Imvelaphi | Shanghai, China |
| Uphawu | Ruifu Chemical |
| Izinto | ImiGangatho yokuHlola | Iziphumo |
| Imbonakalo | Mhlophe ukuya kwi-Off-White Powder | Iyahambelana |
| Indawo yokunyibilika | 242.0~247.0℃ | 243.6 ~ 244.5℃ |
| Ilahleko ekomisweni | <0.50% | 0.15% |
| Intsalela kwi-Ignition | <0.20% | 0.11% |
| Ukungacoceki Okukodwa | <0.50% | <0.30% |
| Ukungcola ngokupheleleyo | <1.00% | 0.30% |
| Ubunyulu / Indlela yokuHlalutya | >99.0% (HPLC) | 99.7% |
| I-1H NMR Spectrum | Ngokungqinelana noLwakhiwo | Iyahambelana |
| Ukuqukumbela | Imveliso ivavanyiwe kwaye ihambelana neenkcukacha ezinikiweyo | |
| Isicelo | Phakathi kweGefitinib (CAS: 184475-35-2) | |
Umqulu:Ibhotile eFluorinated, iAluminium foil bag, 25kg/Cardboard Drum, okanye ngokwemfuno yomthengi.
Imeko yoGcino:Gcina isikhongozeli sivalwe ngokuqinileyo kwaye usigcine kwindawo epholileyo, eyomileyo (2~8℃) kunye nendawo yokugcina impahla engena moya ikude kwizinto ezingahambelaniyo.Khusela ukukhanya kunye nokufuma.
Ukuhambisa ngenqanawe:Zisa kwihlabathi liphela ngomoya, ngeFedEx / DHL Express.Ukubonelela ngokukhawuleza nangokuthembekileyo.
Ukuthenga njani?Nceda uqhagamshelaneDr. Alvin Huang: sales@ruifuchem.com or alvin@ruifuchem.com
Amava Eminyaka Eli-15?Sineminyaka engaphezu kwe-15 yamava ekwenziweni nasekuthumeleni kumazwe angaphandle uluhlu olubanzi oluphezulu lwamayeza aphakathi okanye amachiza alungileyo.
Iimarike eziphambili?Thengisa kwimarike yasekhaya, eMntla Melika, eYurophu, eIndiya, eKorea, eJapan, eOstreliya, njl.
Iingenelo?Umgangatho ophezulu, ixabiso elifikelelekayo, iinkonzo zengcali kunye nenkxaso yobugcisa, ukuhanjiswa ngokukhawuleza.
UmgangathoIsiqinisekiso?Inkqubo yokulawula umgangatho ongqongqo.Izixhobo zobuchwephesha zokuhlalutya ziquka i-NMR, LC-MS, GC, HPLC, ICP-MS, UV, IR, OR, KF, ROI, LOD, MP, Clarity, Solubility, Microbial limit test, njl.
Iisampulu?Uninzi lweemveliso zibonelela ngeesampulu zasimahla zokuvavanya umgangatho, iindleko zokuthumela kufuneka zihlawulwe ngabathengi.
Factory Audit?Uphicotho-zincwadi lwasefektri wamkelekile.Nceda wenze idinga kwangaphambili.
MOQ?Akukho MOQ.Umyalelo omncinci wamkelekile.
Ixesha lokuzisa? Ukuba ngaphakathi kwesitokhwe, ukuhanjiswa kweentsuku ezintathu kuqinisekisiwe.
Ezothutho?Nge-Express (FedEx, DHL), ngoMoya, ngoLwandle.
Amaxwebhu?Emva kwenkonzo yokuthengisa: I-COA, i-MOA, i-ROS, i-MSDS, njl.
Udibaniso lweSiko?Inokubonelela ngeenkonzo zesiko lokudibanisa ukuze zilungele iimfuno zakho zophando.
Immimiselo yokuhlawula?I-invoyisi yeProforma iya kuthunyelwa kuqala emva kokuqinisekiswa kwe-odolo, efakwe kwiinkcukacha zethu zebhanki.Intlawulo nge-T / T (i-Telex Transfer), i-PayPal, i-Western Union, njl.
I-7-Methoxy-6- (3-Morpholin-4-ylpropoxy) quinazolin-4 (3H)-Enye (i-CAS: 199327-61-2) iphakathi / ukungcola kweGefitinib (CAS: 184475-35-2).I-Gefitinib liyeza elithile elichasene ne-tumor elijoliswe kunyango eliphuhliswe ngu-AstraZeneca, e-UK.I-Gefitinib lichiza lokuqala elijoliswe kwimolekyuli kunyango lomhlaza wemiphunga weseli ongeyonxalenye encinci.Isebenza ngokuthintela ngokukhethekileyo indlela yokudluliselwa kwesignali ye-epidermal growth factor receptor tyrosine kinase (EGFR-TK).Ngo-Agasti ka-2002, i-Gefitinib yaqala ukuthengiswa e-Japan njengonyango lodidi lokuqala lomhlaza wemiphunga weseli ongenguwo omncinci phantsi kwegama lokurhweba elithi Iressa.NgoMeyi ka-2003, i-US Food and Drug Administration yavuma i-Gefitinib njengonyango lwe-monotherapy yodidi lwesithathu kwizigulana ezinomhlaza wemiphunga weseli engeyiyo encinci nengazange isebenze ngamachiza e-anticancer asekwe kwiplatinam kunye ne-docetaxel chemotherapy.Okwangoku, i-Gefitinib ivunyiwe yi-Australia, i-Japan, i-Argentina, i-Singapore kunye ne-South Korea kunyango lwe-non-small cell lung cancer.Ngomhla wama-28 kaFebruwari, i-2005, i-China Food and Drug Administration yavuma i-Gefitinib kunyango lomhlaza wemiphunga we-cell cell ophucukileyo okanye one-metastatic engeyiyo encinci (NSCLC) eyayifumene ichemotherapy ngaphambili.Ayikavunywa okwangoku ukuba isetyenziswe njengonyango lodidi lokuqala lwe-NSCLC ephucukileyo.Ngomhla woku-1 kuJulayi, ka-2009, i-Arhente yaMayeza yaseYurophu yavuma ngokusesikweni i-Gefitinib kunyango lodidi lokuqala, lodidi lwesibini nolwesithathu lomhlaza wemiphunga weseli ophucukileyo okanye onesimetastatic ongengowomncinci omncinci noguqulo lwemfuza ye-EGFR kubantu abadala.
